Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Hydrocortisone on Range of Motion After Total Knee Arthroplasty
NCT04082533Phase 4Active, not recruiting
- Sponsor
- Hospital for Special Surgery
- Start
- Jul 2019
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of hydrocortisone in Arthrofibrosis and pain (4 arms), sponsored by Hospital for Special Surgery. Primary endpoint: Postoperative Range of Motion at 6 weeks. Started Jul 2019; status: active, not recruiting.
02
Drugs
hydrocortisone
03
Conditions
Arthrofibrosispain
Beyond the preview
Go deeper on NCT04082533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04082533.